Calithera Biosciences
Founded Year
2010Stage
IPO | IPOTotal Raised
$101.24MDate of IPO
10/2/2014Market Cap
0.00BStock Price
0.36About Calithera Biosciences
Calithera Biosciences, formerly Protein Activation Therapeutics, develops therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymes. The company's first program is focused on developing activators of caspases, the proteases that induce apoptosis, for the treatment of cancer. The approach of discovering activators of enzymes has the potential to be a unique and broadly applicable technology platform for developing therapies to multiple oncology indications. The company was founded in 2010 and is based in South San Francisco, California.
Missing: Calithera Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Calithera Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Calithera Biosciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Calithera Biosciences is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Calithera Biosciences Patents
Calithera Biosciences has filed 48 patents.
The 3 most popular patent topics include:
- Immunology
- Clusters of differentiation
- Experimental cancer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/1/2021 | 6/28/2022 | Stereochemistry, Cannabinoids, Designer drugs, Fluoroarenes, Carboxamides | Grant |
Application Date | 2/1/2021 |
|---|---|
Grant Date | 6/28/2022 |
Title | |
Related Topics | Stereochemistry, Cannabinoids, Designer drugs, Fluoroarenes, Carboxamides |
Status | Grant |
Latest Calithera Biosciences News
May 20, 2023
Special Meeting to be Held on or about June 29, 2023 with a Record Date... The post Calithera Biosciences Announces Update on Complete Liquidation and Dissolution first appeared on IT Business Net.
Calithera Biosciences Frequently Asked Questions (FAQ)
When was Calithera Biosciences founded?
Calithera Biosciences was founded in 2010.
Where is Calithera Biosciences's headquarters?
Calithera Biosciences's headquarters is located at 343 Oyster Point Blvd, South San Francisco.
What is Calithera Biosciences's latest funding round?
Calithera Biosciences's latest funding round is IPO.
How much did Calithera Biosciences raise?
Calithera Biosciences raised a total of $101.24M.
Who are the investors of Calithera Biosciences?
Investors of Calithera Biosciences include Delphi Ventures, Morgenthaler Ventures, Advanced Technology Ventures, T. Rowe Price, Longwood Fund and 5 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.